|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H1B |
Gene summary for HIST1H1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H1B | Gene ID | 3009 |
| Gene name | H1.5 linker histone, cluster member | |
| Gene Alias | H1 | |
| Cytomap | 6p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | P16401 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3009 | HIST1H1B | LZE24T | Human | Esophagus | ESCC | 4.15e-02 | 1.14e-01 | 0.0596 |
| 3009 | HIST1H1B | LZE21T | Human | Esophagus | ESCC | 1.57e-07 | 6.39e-01 | 0.0655 |
| 3009 | HIST1H1B | P1T-E | Human | Esophagus | ESCC | 2.65e-12 | 7.37e-01 | 0.0875 |
| 3009 | HIST1H1B | P2T-E | Human | Esophagus | ESCC | 2.02e-06 | 5.50e-01 | 0.1177 |
| 3009 | HIST1H1B | P4T-E | Human | Esophagus | ESCC | 1.36e-04 | 2.16e-01 | 0.1323 |
| 3009 | HIST1H1B | P5T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.20e-01 | 0.1327 |
| 3009 | HIST1H1B | P10T-E | Human | Esophagus | ESCC | 3.75e-03 | 2.99e-01 | 0.116 |
| 3009 | HIST1H1B | P12T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.10e-01 | 0.1122 |
| 3009 | HIST1H1B | P15T-E | Human | Esophagus | ESCC | 1.31e-02 | 1.17e-01 | 0.1149 |
| 3009 | HIST1H1B | P16T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.71e-01 | 0.1153 |
| 3009 | HIST1H1B | P17T-E | Human | Esophagus | ESCC | 4.79e-04 | 5.35e-01 | 0.1278 |
| 3009 | HIST1H1B | P27T-E | Human | Esophagus | ESCC | 8.40e-04 | 2.08e-01 | 0.1055 |
| 3009 | HIST1H1B | P31T-E | Human | Esophagus | ESCC | 4.31e-06 | 2.49e-01 | 0.1251 |
| 3009 | HIST1H1B | P36T-E | Human | Esophagus | ESCC | 7.72e-03 | 2.46e-01 | 0.1187 |
| 3009 | HIST1H1B | P37T-E | Human | Esophagus | ESCC | 1.87e-02 | 1.24e-01 | 0.1371 |
| 3009 | HIST1H1B | P48T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.27e-01 | 0.0959 |
| 3009 | HIST1H1B | P52T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.75e-01 | 0.1555 |
| 3009 | HIST1H1B | P54T-E | Human | Esophagus | ESCC | 5.82e-06 | 1.64e-01 | 0.0975 |
| 3009 | HIST1H1B | P61T-E | Human | Esophagus | ESCC | 4.08e-06 | 2.12e-01 | 0.099 |
| 3009 | HIST1H1B | P65T-E | Human | Esophagus | ESCC | 1.50e-12 | 4.11e-01 | 0.0978 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H1B | SNV | Missense_Mutation | c.429N>C | p.Lys143Asn | p.K143N | P16401 | protein_coding | tolerated(0.08) | possibly_damaging(0.796) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| HIST1H1B | SNV | Missense_Mutation | novel | c.32N>G | p.Thr11Ser | p.T11S | P16401 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-A8-A08X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | PD |
| HIST1H1B | SNV | Missense_Mutation | c.564N>C | p.Lys188Asn | p.K188N | P16401 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| HIST1H1B | insertion | Frame_Shift_Ins | novel | c.134_135insTATTCTCCTTACTGTTTTTTTCTGTAATAAGGGG | p.Glu45AspfsTer22 | p.E45Dfs*22 | P16401 | protein_coding | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| HIST1H1B | insertion | Nonsense_Mutation | novel | c.201_202insTTTACCCATGCAGTCTGTTATTAGAGTAT | p.Ala68PhefsTer8 | p.A68Ffs*8 | P16401 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| HIST1H1B | SNV | Missense_Mutation | rs541014157 | c.344C>T | p.Ala115Val | p.A115V | P16401 | protein_coding | tolerated(0.1) | benign(0.041) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HIST1H1B | SNV | Missense_Mutation | c.5N>T | p.Ser2Leu | p.S2L | P16401 | protein_coding | deleterious(0) | benign(0.196) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H1B | SNV | Missense_Mutation | c.564N>C | p.Lys188Asn | p.K188N | P16401 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-FU-A3NI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H1B | SNV | Missense_Mutation | c.564G>C | p.Lys188Asn | p.K188N | P16401 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H1B | deletion | In_Frame_Del | rs758100284 | c.615_629delCGCTAAGCCCAAAGC | p.Pro213_Lys217del | p.P213_K217del | P16401 | protein_coding | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |